Showing results (91-100 of 116) with videos related to

Sort By:
Pageof 12
Bone Marrow Transplantation|October 2, 2019
Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixaforAnna Sureda, Christian Chabannon, Tamás Masszi, et al.
Blood|November 6, 2024
Acute promyelocytic leukemia: long-term outcomes from the HARMONY projectMaria Teresa Voso, Luca Guarnera, Söhren Lehmann, et al.
Leukemia|February 5, 2021
Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMTJordi Esteve, Sebastian Giebel, Myriam Labopin, et al.
The New England Journal of Medicine|January 21, 2016
Assessment of Minimal Residual Disease in Standard-Risk AMLAdam Ivey, Robert K Hills, Michael A Simpson, et al.
The Journal of Experimental Medicine|March 21, 2019
Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AMLFaisal Basheer, George Giotopoulos, Eshwar Meduri, et al.
The Lancet. Haematology|April 30, 2025
Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trialsNicola Potter, Jelena Jovanovic, Adam Ivey, et al.
The Lancet. Oncology|June 9, 2019
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trialJorge E Cortes, Samer Khaled, Giovanni Martinelli, et al.
The Lancet. Oncology|June 4, 2018
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trialJorge Cortes, Alexander E Perl, Hartmut Döhner, et al.
Annals of Hematology|April 18, 2019
The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMTMartin Schmidt-Hieber, Gloria Tridello, Per Ljungman, et al.
Haematologica|April 6, 2006
The effect of prior exposure to imatinib on transplant-related mortalityMichael Deininger, Michael Schleuning, Hilde Greinix, et al.
Pageof 12